References
- AmlingCLBluteMLBergstralhEJSeayTMSlezakJZinckeHLong-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 yearsJ Urol2000164110110510840432
- PotoskyALDavisWWHoffmanRMFive-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostatecancer outcomes studyJ Natl Cancer Inst2004961358136715367568
- ChismDBHanlonALHorwitzEMFeigenbergSJPollackAA comparison of the single and double factor high risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapyInt J Radiat Oncol Biol Phys200459238038515145151
- LeeAKD’AmicoAVUtility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapyJ Clin Oncol200523328192819716278472
- MasonMDSydesMRGlaholmJOral sodium clodronate for nonmetastatic prostate cancer – results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)J Natl Cancer Inst2007991076577617505072
- ZhangTArmstrongAJClinical utility of circulating tumor cells in advanced prostate cancerCurr Oncol Rep2016181326700506
- de BonoJSScherHIMontgomeryRBCirculating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancerClin Cancer Res200814196302630918829513
- StrijbosMHGratamaJWSchmitzPICirculating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxelEur J Cancer201046112027203520399640
- GoodmanOBJrSymanowskiJTLoudyiAFinkLMWardDCVogelzangNJCirculating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancerClin Genitourin Cancer201191313821705286
- ThompsonIThrasherJBAusGGuideline for the management of clinically localized prostate cancer: 2007 updateJ Urol200717762106213117509297
- RoachMHanksGThamesHJrDefining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInt J Radiat Oncol Biol Phys200665496597416798415
- SlovinSFWiltonASHellerGScherHITime to detectable metastatic disease in patients with rising prostate specific antigen values following surgery or radiation therapyClin Cancer Res200511248669867316361552
- ScherHIHellerGMolinaACirculating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancerJ Clin Oncol201533121348135525800753
- GoldkornAElyBQuinnDICirculating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castrationresistant prostate cancerJ Clin Oncol201432111136114224616308
- BrigantiASuardiNGallinaAPredicting the risk of bone metastasis in prostate cancerCancer Treat Rev201440131123896177
- FranciniEPetrioliRRossiGLaeraLRovielloGPSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trialsTumour Biol20143511106011060725195134